Build a Patient-Side AI Visit Documentation and Care-Navigation Tool

A patient-side AI visit documentation and care-navigation tool helps the person receiving care, not the clinician giving it. It might capture and summarize what happened in a visit in plain language, keep track of instructions and medications, prepare questions before an appointment, or navigate the confusing next steps afterward (referrals, follow-ups, understanding a diagnosis). It is the deliberate mirror image of the clinician scribe: the entire $600-million-plus AI notetaker market generated its revenue almost entirely from the clinician side, so the patient side of that exact consultation is, in investors' own framing, equally large and untapped. This is a consumer or consumer-and-partner health tool, and its hardest problems are trust, safety, and distribution rather than the AI itself.

The structural insight is a two-sided interaction with nearly all investment on one side. Clinician scribes absorbed the vast majority of the category's $4.8 billion in funding since 2019, while the patient side of the same visit remains explicitly flagged by investors as comparably large and overlooked. Patients genuinely struggle: they forget most of what is said in a visit, misunderstand instructions, and get lost in fragmented next steps, which drives worse outcomes and wasted care. A tool that reliably helps them capture, understand, and act has clear value, and it can be paid for by consumers directly, by employers and payers who benefit when members follow through, or by providers who want better-informed patients. Because the AI capability is proven on the clinician side, the build risk is lower than the market implies; the real work is earning trust and reaching people.

When one side of a two-sided interaction attracts nearly all the capital, the other side looks empty and unproven, so builders keep piling into the crowded side. That is exactly what happened here: over 100 funded companies chased clinician documentation while the patient side, the person who actually has to remember and act on the visit, was left almost untouched. It stays overlooked because building for patients is harder in the ways that do not show up in a demo (trust, safety, regulatory care, and consumer distribution are all unglamorous), and because the reflex is to copy the funded winners rather than serve the neglected counterpart. The research names this pattern directly: a two-sided category with lopsided investment usually hides a comparably sized, comparably overlooked opportunity on the underserved side, and this is a clean example.